5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow Congenital Bleeding Disorder: new trials by email Literature Review of Congenital Bleeding Disorder trials Research Report on Congenital Bleeding Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors Concizumab, Eptacog alfa - Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 2 | Completed | Novo Nordisk A/S | 26 | 2017-08-10 | 2021-10-22 |
| Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial No treatment given - Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 2 | Completed | Novo Nordisk A/S | 19 | 2015-04-03 | 2019-01-04 |
| Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors activated recombinant human factor VII, long acting - Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 2 | Completed | Novo Nordisk A/S | 23 | 2009-09-01 | 2018-09-05 |
| Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds eptacog alfa (activated), vatreptacog alfa (activated) - Congenital Bleeding Disorder, Haemophilia A | Phase 2 | Completed | Novo Nordisk A/S | 51 | 2007-06-01 | 2017-03-07 |
| Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia activated recombinant human factor VII - Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 2 | Completed | Novo Nordisk A/S | 23 | 2004-03-01 | 2017-01-12 |
Hemophilia A (1) · Hemophilia B (1)
Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1)
Factor VII (1) · concizumab (1) · recombinant FVIIa (1) · vatreptacog alfa (1)
Novo Nordisk A/S (5)
United States (5) · Japan (4) · Malaysia (4) · Brazil (3) · France (3) · South Africa (3) · Spain (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Argentina (2) · Canada (2) · Croatia (2) · Greece (2) · Israel (2) · Italy (2)
PMID 17723130, PMID 22470921, PMID 23578227, PMID 31444162, PMID 35290453
2008 (1), 2015 (1), 2016 (1)